Acorda Therapeutics, Inc. (NASDAQ:ACOR) Stock Quotes and News

Acorda Therapeutics, Inc. (ACOR) 33.09 0.44

Price Open:	32.13	Day's Range:	0.00000 - 40.96000
Price Close:	32.23	52wk Range:	0.00000 - 40.96000
Price Day Change:	0.44	Volume:	268,894
Price % Change:	1.37	Market Cap:	1.303B
Bid:	26.50000	PE Ratio:	8.87
Ask:	33.09000	EPS Diluted:	3.633

Trade ACOR NOW!

The Latest On ACOR

Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA(R) Covering a Range of Dosage Strengths 5/20/13 7:30am

Acorda Therapeutics Announces New US Patent for AMPYRA 5/20/13 7:05am

Market Wrap for Tuesday, April 16: Stock Market Rebounds Strongly From Monday's Sharp Losses 4/16/13 4:21pm

Market Wrap for Monday, April 15: Major Sell-Off Sweeps Wall Street; Gold Plunges to 2-Year Low 4/15/13 4:33pm

Mid-Afternoon Market Update: Explosions Rock Downtown Boston, Authorities Unsure if Explosive Devices 4/15/13 3:41pm

Mid-Day Market Update: Sprint Surges On Dish Network Offer, AuRico Gold Tumbles 4/15/13 1:15pm

Stocks Hitting 52-Week Highs 4/15/13 11:23am

Acorda Therapeutics Announces Positive AMPYRA Phase 2 Data in People with Post-Stroke Deficits 4/15/13 8:03am

Acorda Therapeutics Could Be a Stock to Watch in 2013 2/4/13 4:21pm

UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts 1/3/13 9:26am

A Peek Into The Market Before The Trading Starts 12/21/12 8:17am

Acorda Therapeutics Completes Neuronex Acquisition 12/21/12 7:16am

Press Releases

CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis 5/21/13 Business Wire

Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis 5/21/13 Business Wire

Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths 5/20/13 Business Wire

Acorda Therapeutics' Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine 5/17/13 Business Wire

Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013 4/25/13 Business Wire

Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting 3/6/13 Business Wire

Acorda Therapeutics Presents GGF2 Preclinical Stroke Data at International Stroke Conference 2/7/13 Business Wire

Acorda Therapeutics to Present at Leerink Swann Global Healthcare Conference 2/7/13 Business Wire

Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Financial Results on February 13, 2013 2/6/13 Business Wire

Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition 12/21/12 Business Wire

Get the latest ACOR stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Acorda Therapeutics, Inc. stock price.

Partner Headlines

Alkermes Earnings Beat Estimates, But Outlook Unclear 5/23/13

Additional Patent for Acorda's Ampyra - Analyst Blog 5/22/13

Alkermes Earnings Seen Rising, But Sales Uncertain 5/22/13

Acorda Incurs Loss, Maintains Guidance - Analyst Blog 5/6/13

Acorda Initiates Study on rHIgM22 - Analyst Blog 4/25/13

Biotech Alkermes Poised To Swell On Pipeline Wins 4/16/13

Acorda Therapeutics 4/15/13

Acorda Reports Data on Epilepsy Drug - Analyst Blog 3/26/13

Acorda Presents GGF2 Data - Analyst Blog 3/8/13

Earnings Miss at Acorda - Analyst Blog 2/14/13

Zacks Rank #5 Additions for Thursday - Tale of the Tape 2/14/13